On 2017 Oct 07, Ruth Gabizon commented:

Definitely agree. Indeed the utility of EAE as an MS model has always been questioned. Many treatment strategies that were usefull for EAE had no effects on humans, which is the case for many reagents in all animal models of diseases. However, it is important to acknowledge that all MS treatments used today were first shown to be active in EAE models

On 2017 Sep 30, Alessandro Rasman commented:

Very interesting study. It is important now to test it on humans because there are doubts about the utility of the EAE model in the MS (1). References: 1. Behan, Peter O., and Abhijit Chaudhuri. "EAE is not a useful model for demyelinating disease." Multiple Sclerosis and Related Disorders 3.5 (2014): 565-574.

On 2017 Sep 30, Alessandro Rasman commented:

Very interesting study. It is important now to test it on humans because there are doubts about the utility of the EAE model in the MS (1). References: 1. Behan, Peter O., and Abhijit Chaudhuri. "EAE is not a useful model for demyelinating disease." Multiple Sclerosis and Related Disorders 3.5 (2014): 565-574.

On 2017 Oct 07, Ruth Gabizon commented:

Definitely agree. Indeed the utility of EAE as an MS model has always been questioned. Many treatment strategies that were usefull for EAE had no effects on humans, which is the case for many reagents in all animal models of diseases. However, it is important to acknowledge that all MS treatments used today were first shown to be active in EAE models